APR 07, 2016 6:00 AM PDT

Ligand-Targeted Therapies for Cancer and Autoimmune Diseases

Speakers
  • Director of the Purdue Center for Drug Discovery Ralph C. Corley Distinguished Professor Department of Chemistry, Purdue University
    Biography
      Dr. Philip S. Low is the Director of the Purdue University Center for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry. Dr. Low has spent over 39 years exploring novel methods for drug targeting, and characterizing the structure, function, and pathologies of the erythrocyte membrane. He has published >350 scientific articles and has >50 US patents/patents pending. Eight drugs stemming from his research are undergoing human clinical trials and three companies (Endocyte Inc., OnTarget Laboratories Inc., and HuLow LLC) have been founded to commercialize his discoveries. Dr. Low has received an NIH MERIT Award, the ACS Award for Cancer Research (Sosnovsky Award), the AACR Award for Outstanding Chemistry in Cancer Research, both of Purdue's awards for outstanding research (McCoy and Sigma Xi Awards), the University's highest career achievement award (Morrill Award), and numerous other National and International awards. Dr. Low received his B.S. in Chemistry from Brigham Young University (1971) and his Ph.D. in Biochemistry from UCSD (1975).

    Abstract:

    We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation of the folate receptor on cancers of the ovary, lung, kidney, endometrium and breast to target imaging and therapeutic agents to these cancers. Clinical trials of six folate-linked drugs demonstrate that the ligand-targeting strategy holds promise for increasing drug potency while reducing unwanted toxicity. Data on treatment of tumor-bearing mice, dogs, and humans will be presented. We have also developed a targeting ligand that selectively delivers attached drugs to PSMA on prostate cancer cells. Imaging and therapeutic studies suggest that this targeting ligand can not only improve the diagnosis of prostate cancer, but also enhance treatment of the disease. Recent pre-clinical and clinical data on this targeting ligand confirm this anticipation. Additional cancer-specific ligands that target malignancies of the bladder, pancreas, stomach, brain, liver, colon, skin and esophagus are also under investigation. Moreover, use of these ligands to “light up” cancer tissues with tumor-targeted fluorescent dyes during surgeries are being developed and videos of recent surgeries of ovarian and lung cancers will be presented. Finally, ligand-targeted imaging and therapeutic agents for a number of autoimmune and inflammatory diseases (e.g. rheumatoid arthritis, Crohn’s disease, psoriasis, atherosclerosis, osteoarthritis, etc.) will also be described.


    Show Resources
    You May Also Like
    SEP 05, 2019 4:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 4:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    NOV 07, 2019 10:00 AM PST
    C.E. CREDITS
    NOV 07, 2019 10:00 AM PST
    DATE: November 7, 2019TIME: 10:00am PST, 1:00pm EST Studying the pathogenesis of diabetes requires detailed analysis of the pancreatic islet microenvironment and its numerous c...
    Loading Comments...
    Show Resources